Place of proton radiotherapy in future radiotherapy practice

Seminars in Radiation Oncology

Volumn 23, Issue 2, 2013, Pages 149-153

  Zips, Daniel ^a   Baumann, Michael ^b  

^a UNIVERSITY OF TÜBINGEN   (Germany)

^b UNIVERSITY HOSPITAL CARL GUSTAV CARUS   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

PROTON; RADIOSENSITIZING AGENT;

ARTICLE; BIOMEDICAL TECHNOLOGY ASSESSMENT; CANCER PATIENT; CANCER RADIOTHERAPY; CLINICAL PRACTICE; CLINICAL TRIAL (TOPIC); COST EFFECTIVENESS ANALYSIS; DIAGNOSTIC ACCURACY; DOSIMETRY; DRUG TARGETING; EVIDENCE BASED MEDICINE; HEAD AND NECK CANCER; HUMAN; IMAGE QUALITY; INTENSITY MODULATED RADIATION THERAPY; LINEAR ENERGY TRANSFER; NEOPLASM; ONCOLOGY; PERSONALIZED MEDICINE; PRIORITY JOURNAL; PROSTATE CANCER; PROTON THERAPY; QUALITY OF LIFE; RADIATION DOSE DISTRIBUTION; RADIATION DOSE FRACTIONATION;

CLINICAL TRIALS AS TOPIC; DOSE FRACTIONATION; FORECASTING; HUMANS; INDIVIDUALIZED MEDICINE; MOLECULAR TARGETED THERAPY; NEOPLASMS; PROTON THERAPY; RADIATION ONCOLOGY; RADIOMETRY; RADIOTHERAPY DOSAGE; TECHNOLOGY ASSESSMENT, BIOMEDICAL;

EID: 84875252977     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2012.11.007     Document Type: Article

References (36)

1. Sullivan R., peppercorn J., Sikora K., et al. Delivering affordable cancer care in high-income countries. Lancet Oncol 2011, 12:933-980.
2. Dearnaley D.P., Khoo V.S., Norman A.R., et al. Comparison of radiation side-effects of conformal and conventional radiotherapy in prostate cancer: A randomised trial. Lancet 1999, 353:267-272.
3. Nutting C.M., Morden J.P., Harrington K.J., et al. Parotid-sparing intensity modulated versus conventional radiotherapy in head and neck cancer (PARSPORT): A phase 3 multicentre randomised controlled trial. Lancet Oncol 2011, 12:127-136.
4. Shah A., Efstathiou J.A., Paly J.J., et al. Prospective preference assessment of patients' willingness to participate in a randomized controlled trial of intensity-modulated radiotherapy versus proton therapy for localized prostate cancer. Int J Radiat Oncol Biol Phys 2012, 83:e13-e19.
5. van der Laan HP, van de Water TA, van Herpt HE, et al: The potential of intensity-modulated proton radiotherapy to reduce swallowing dysfunction in the treatment of head and neck cancer: A planning comparative study. Acta Oncol (in press).
6. van der Laan H.P., Christianen M.E., Bijl H.P., et al. The potential benefit of swallowing sparing intensity modulated radiotherapy to reduce swallowing dysfunction: An in silico planning comparative study. Radiother Oncol 2012, 103:76-81.
7. Boomsma M.J., Bijl H.P., Christianen M.E., et al. A prospective cohort study on Radiation-induced hypothyroidism: Development of an NTCP model. Int J Radiat Oncol Biol Phys 2012, 84:e351-e356.
8. Beetz I., Schilstra C., van der Schaaf A., et al. NTCP models for patient-rated xerostomia and sticky saliva after treatment with intensity modulated radiotherapy for head and neck cancer: The role of dosimetric and clinical factors. Radiother Oncol 2012, 105:101-106.
9. Christianen M.E., Schilstra C., Beetz I., et al. Predictive modelling for swallowing dysfunction after primary (chemo)radiation: Results of a prospective observational study. Radiother Oncol 2012, 105:107-114.
10. Beetz I., Schilstra C., van Luijk P., et al. External validation of three dimensional conformal radiotherapy based NTCP models for patient-rated xerostomia and sticky saliva among patients treated with intensity modulated radiotherapy. Radiother Oncol 2011, 105:94-100.
11. Beetz I., Schilstra C., Burlage F.R., et al. Development of NTCP models for head and neck cancer patients treated with three-dimensional conformal radiotherapy for xerostomia and sticky saliva: The role of dosimetric and clinical factors. Radiother Oncol 2011, 105:86-93.
12. Roelofs E., Engelsman M., Rasch C., et al. Results of a multicentric in silico clinical trial (ROCOCO): Comparing radiotherapy with photons and protons for non-small cell lung cancer. J Thorac Oncol 2012, 7:165-176.
13. Langendijk J.A. Open prediction of expected gain from proton therapy in individual patients based on NTCP predictive modelling: Final results of ALLEGRO project. Radiother Oncol 2012, 102:S166-S167.
14. Dijkema T., Terhaard C.H., Roesink J.M., et al. Large cohort dose-volume response analysis of parotid gland function after radiotherapy: Intensity-modulated versus conventional radiotherapy. Int J Radiat Oncol Biol Phys 2008, 72:1101-1109.
15. Konings A.W., Cotteleer F., Faber H., et al. Volume effects and region-dependent radiosensitivity of the parotid gland. Int J Radiat Oncol Biol Phys 2005, 62:1090-1095.
16. van Luijk P., Faber H., Schippers J.M., et al. Bath and shower effects in the rat parotid gland explain increased relative risk of parotid gland dysfunction after intensity-modulated radiotherapy. Int J Radiat Oncol Biol Phys 2009, 74:1002-1005.
17. Bentzen S.M. Randomized controlled trials in health technology assessment: Overkill or overdue?. Radiother Oncol 2008, 86:142-147.
18. Teh B.S., Bastasch M.D., Wheeler T.M., et al. IMRT for prostate cancer: Defining target volume based on correlated pathologic volume of disease. Int J Radiat Oncol Biol Phys 2003, 56:184-191.
19. Daisne J.F., Duprez T., Weynand B., et al. Tumor volume in pharyngolaryngeal squamous cell carcinoma: Comparison at CT, MR imaging, and FDG PET and validation with surgical specimen. Radiology 2004, 233:93-100.
20. Giraud P., Antoine M., Larrouy A., et al. Evaluation of microscopic tumor extension in non-small-cell lung cancer for three-dimensional conformal radiotherapy planning. Int J Radiat Oncol Biol Phys 2000, 48:1015-1024.
21. Grills I.S., Fitch D.L., Goldstein N.S., et al. Clinicopathologic analysis of microscopic extension in lung adenocarcinoma: Defining clinical target volume for radiotherapy. Int J Radiat Oncol Biol Phys 2007, 69:334-341.
22. Yuan S., Meng X., Yu J., et al. Determining optimal clinical target volume margins on the basis of microscopic extracapsular extension of metastatic nodes in patients with non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 2007, 67:727-734.
23. Thomas S.J. Margins for treatment planning of proton therapy. Phys Med Biol 2006, 51:1491-1501.
24. Horsman MR, Mortensen LS, Petersen JB, et al: Imaging hypoxia to improve radiotherapy outcome. Nat Rev Clin Oncol (in press).
25. Dirix P., Vandecaveye V., De Keyzer F., et al. Dose painting in radiotherapy for head and neck squamous cell carcinoma: Value of repeated functional imaging with (18)F-FDG PET, (18)F-fluoromisonidazole PET, diffusion-weighted MRI, and dynamic contrast-enhanced MRI. J Nucl Med 2009, 50:1020-1027.
26. Zips D., Zöphel K., Abolmaali N., et al. Exploratory prospective trial of hypoxia-specific PET imaging during radiochemotherapy in patients with locally advanced head-and-neck cancer. Radiother Oncol 2012, 105:21-28.
27. Toustrup K., Sørensen B.S., Lassen P., et al. Gene expression classifier predicts for hypoxic modification of radiotherapy with nimorazole in squamous cell carcinomas of the head and neck. Radiother Oncol 2012, 102:122-129.
28. Thorwarth D., Soukup M., Alber M. Dose painting with IMPT, helical tomotherapy and IMXT: A dosimetric comparison. Radiother Oncol 2008, 86:30-34.
29. Baumann M. Keynote comment: Radiotherapy in the age of molecular oncology. Lancet Oncol 2006, 7:786-787.
30. Shakirin G., Braess H., Fiedler F., et al. Implementation and workflow for PET monitoring of therapeutic ion irradiation: A comparison of in-beam, in-room, and off-line techniques. Phys Med Biol 2011, 56:1281-1298.
31. Grills I.S., Hope A.J., Guckenberger M., et al. A collaborative analysis of stereotactic lung radiotherapy outcomes for early-stage non-small-cell lung cancer using daily Online cone-beam computed tomography image-guided radiotherapy. J Thorac Oncol 2012, 7:1382-1393.
32. Siva S., MacManus M., Ball D. Stereotactic radiotherapy for pulmonary oligometastases: A systematic review. J Thorac Oncol 2010, 5:1091-1099.
33. Bentzen S.M., Agrawal R.K., et al. The UK standardisation of breast radiotherapy (START) trial A of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet Oncol 2008, 9:331-341. START Trialists' Group.
34. Bentzen S.M., Agrawal R.K., et al. The UK standardisation of breast radiotherapy (START) trial B of radiotherapy hypofractionation for treatment of early breast cancer: A randomised trial. Lancet 2008, 371:1098-1107. START Trialists' Group.
35. Baumann M., Herrmann T., Koch R., et al. Final results of the randomized phase III CHARTWEL-trial (ARO 97-1) comparing hyperfractionated-accelerated versus conventionally fractionated radiotherapy in non-small cell lung cancer (NSCLC). Radiother Oncol 2011, 100:76-85.
36. Mauguen A., Le Péchoux C., Saunders M.I., et al. Hyperfractionated or accelerated radiotherapy in lung cancer: An individual patient data meta-analysis. J Clin Oncol 2012, 30:2788-2797.